Merck’s Keytruda isn’t letting rival Opdivo from Bristol-Myers Squibb soak up all the November regulatory attention. The immuno-oncology med has taken the…

Many drugmakers have voiced displeasure about England’s cost watchdogs following negative assessments for promising but costly new meds. Now, though, Pfizer is…

Mylan flatly refused to testify at a committee hearing convened by Sen. Charles Grassley, who's questioning the EpiPen maker's ultraquick Medicaid-…

It’s official: To promote drugs in Chicago, you’ll need a $750 license—and some serious record-keeping skills.

GSK has tapped a new China boss, its latest in a series of personnel changes heading into next year.

When drug-price critic Hillary Clinton unexpectedly lost the election last week, it was little surprise that shares of drug companies rallied, with the Nasdaq…

An analysis of recently launched meds holds some clues to successful—and not so successful—rollouts.

Teva is trying to clean the slate on its history of allegedly paying bribes in foreign countries and has put aside more than half a billion dollars to cover…

Regulatory